Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy
Plain-language summary
This Phase 3 trial is comparing different first-line treatment approaches for people newly diagnosed with a type of T-cell lymphoma called AITL. Patients are randomly assigned to different treatment groups to see which approach works best. It is widely available at 158 US locations.
Who can join (key eligibility)
- Age 18 Years to 75 Years years
- Newly diagnosed, not yet treated
- Must be well enough for treatment (adequate performance status)
- May require specific number of prior treatments
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
Autologous Hematopoietic Stem Cell Transplantation (PROCEDURE): Undergo ASCT | Best Practice (OTHER): Receive standard of care observation | Biospecimen Collection (PROCEDURE): Undergo blood sample collection | Bone Marrow Aspiration (PROCEDURE): Undergo bone marrow aspiration and biopsy | Bone Marrow Biopsy (PROCEDURE): Undergo bone marrow aspiration and biopsy | Computed Tomography (PROCEDURE): Undergo CT or PET/CT | High Dose Chemotherapy (DRUG): Receive high dose chemotherapy | Leukapheresis (PROCEDURE): Undergo leukapheresis | Positron Emission Tomography (PROCEDURE): Undergo PET/CT | Stem Cell Mobilization Therapy (DRUG): Receive stem cell mobilization therapy
- Drugs / treatments
- Autologous Hematopoietic Stem Cell Transplantation, Best Practice, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, High Dose Chemotherapy, Leukapheresis, Positron Emission Tomography, Stem Cell Mobilization Therapy
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details